Embargoed: 12:01 a.m. PT
March 24, 2015

Routine bisphosphonate treatment for women over age 65 who sustain a wrist fracture could prevent nearly 95,000 hip fractures, but at a significant cost

Treatment costs estimated at $2 billion annually, or $205,500 per avoided hip fracture

LAS VEGASOsteoporosis is a disease of progressive bone loss affecting more than 44 million Americans and contributing to an estimated 2 million bone fractures each year. A new study presented today at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that routine bisphosphonate treatment of women over 65 who sustain a distal radius (wrist) fracture—one of the most common fractures associated with osteoporosis—could significantly reduce the risk for additional fractures, primarily hip fractures, but at an estimated cost of more than $2 billion annually.

 

Over 50 percent of men and women over the age of 80 meet diagnostic criteria for osteoporosis placing them at increased risk for bone fractures, including hip fractures, which cause an estimated 300,000 unplanned hospital admissions in the U.S. each year. The lifetime cost of a hip fracture is estimated at $81,300, of which approximately 44 percent of the costs are associated with nursing facility expenses. Bisphosphonates, a drug known to increase bone mass and prevent fractures, has been associated with atypical femur fractures in a small, but significant number of patients.

 

Researchers reviewed existing literature and Medicare data to determine distal radius fracture incidence and age-specific hip fracture rates after distal radius fracture with and without bisphosphonate treatment. A model was then created to determine future fracture rates with and without treatment, and related costs.

 

The model predicted 357,656 lifetime hip fractures following distal radius fracture in all females age 65 and older in the U.S. If these patients received regular bisphosphonate treatment following a distal radius fracture, the number of hip fractures would drop to 262,767 over the lifetime of these patients; however, an estimated 19,464 patients would suffer an atypical femur fracture as a result of the treatment.

 

The cost of routine bisphosphonate treatment, including the cost for treating associated atypical femur fractures, comes to a lifetime total of $19.5 billion, or approximately $205,534 per avoided hip fracture.

 

“Our study suggests that routine universal utilization of bisphosphonates in elderly women after distal radius fracture would not be economically advantageous despite the cost savings associated with reduction of the hip fracture burden in that population,” said lead study author, Suneel B. Bhat, MD, an orthopaedic surgery resident at the Rothman Institute in Philadelphia, Pa.

 

The study authors also hypothesize that the cost of bisphosphonates would need to drop to $70 per patient each year, from the current average annual wholesale cost of $1,485 per patient, to make the treatment affordable to every patient age 65 and older following a wrist fracture. In addition, selecting patients at lower risk for atypical femur fractures for treatment may reduce the number of bisphosphonate-related fractures. Confirming patient osteoporosis and fracture risk through a DEXA Scan (dual X-ray Absorptiometry) before prescribing bisphosphonates remains the most cost-effective method for treating osteoporosis and avoiding subsequent fractures.


# # #


Study abstract


View 2015 AAOS Annual Meeting disclosure statements


About AAOS


Follow us on Facebook.com/AAOS1 and Twitter.com/AAOS1

Orthopaedic surgeons
restore mobility, reduce pain and provide value; they help people get back to work and to independent, productive lives. Visit ANationInMotion.org to read successful
orthopaedic stories.

For more information on bone and joint health, visit Orthoinfo.org.

 

Print   Download Print-friendly PDF

 
 
Multimedia Gallery

Click here to view and download images and videos
from our multimedia gallery.
  Ortho Stats

Ortho Stats & Facts

Click here to find data
to supplement your news.

Join Us
Facebook Twitter YouTube Google+

 

 
Share
Facebook Twitter Share Email
 
  Contacts

For inquiries on this release, contact :

Kristina Goel
P: 847-384-4034 • M: 312-388-5241 • goel@aaos.org

Lauren Pearson Riley
P: 847-384-4031 • M: 708-227-1773 • pearson@aaos.org

Click here to view Award Winner releases.

Click here to view Announcements.

 
 
 
TUESDAY, MARCH 24

Child pedestrians more likely to be struck by motor vehicles in the spring months, while unsupervised, near schools and bus stops

Spinal surgery diminishes low back pain, improves sexual function

Hip replacement patients may be able to safely drive as early as two weeks following surgery

Running barefoot may increase injury risk in older, more experienced athletes

The price of delirium: New study finds nearly half of patients have delirium before and after hip fracture surgery, diminishing outcomes and increasing care costs

Routine bisphosphonate treatment for women over age 65 who sustain a wrist fracture could prevent nearly 95,000 hip fractures, but at a significant cost

Men have a higher level of function before and after total knee replacement surgery

Diabetes, previous joint pain and overall physical health predicts arthritis pain

WEDNESDAY, MARCH 25

Majority of parents, caregivers of youth baseball pitchers unaware of safe pitching practices designed to prevent overuse injuries

Study identifies smoking, obesity, alcohol abuse and depressive disorders as low back pain risk factors

THURSDAY, MARCH 26

Middle-age hip replacements nearly double from 2002-2011, outpacing growth in elderly population

Stem cells may significantly improve tendon healing, reduce retear risk in rotator cuff surgery

Black, Hispanic patients more likely to be readmitted to the hospital for a complication within 30 days following hip or knee replacement surgery

Women fare better than men following total knee, hip replacement

FRIDAY, MARCH 27

More than one-third of Division I college athletes may have low vitamin D levels